
Concord Biotech Ltd. share price
NSE: CONCORDBIO · Healthcare
₹581.00 -2.19%
Closing price data, updated 17 Nov 2026. 52-week range: -28.1% from high, +17.7% above low.
Price₹581.00
Market cap₹6,078 Cr
P/E21.6
P/B2.93
ROE13.6%
ROCE16.7%
Debt / equity0.00
Dividend yield0.00%
EPS₹26.84
Book value₹198.42
Operating margin29.1%
Dipscan score57 / 100
Share: WhatsAppX / TwitterTelegram
Concord Biotech Ltd. shareholding pattern
As of Sep 2026: Promoters 44.09%, FIIs 7.28%, DIIs 10.95%, Government 0.00%, Public 8.81%, Others 28.87%.
| Holder | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 |
|---|---|---|---|---|---|---|
| Promoters | 44.09% | 44.08% | 44.08% | 44.08% | 44.08% | 44.08% |
| FIIs | 7.28% | 7.52% | 7.80% | 7.58% | 8.03% | 9.11% |
| DIIs | 10.95% | 9.36% | 9.22% | 9.58% | 9.55% | 8.87% |
| Government | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public | 8.81% | 8.23% | 8.09% | 8.11% | 7.77% | 7.43% |
| Others | 28.87% | 30.81% | 30.81% | 30.64% | 30.56% | 30.51% |
| No. of Shareholders | 88,365 | 83,325 | 82,249 | 81,815 | 82,650 | 82,045 |
As filed by the company with the exchanges.
Returns
| 1 day | 1 week | 1 month | 3 months | 6 months | 1 year |
|---|---|---|---|---|---|
| -2.19% | -8.16% | -15.93% | -20.11% | +1.93% | -20.06% |
Growth
| Sales growth, 3 years | +8.0% |
| Sales growth, 5 years | – |
| Profit growth, 3 years | +2.8% |
| Profit growth, 5 years | – |
| Latest quarter sales vs last year | +25.1% |
| Latest quarter profit vs last year | +11.1% |
Strengths and weaknesses
Strengths
- Company has reduced debt.
- Company is almost debt free.
- Company has been maintaining a healthy dividend payout of 28.2%
Weaknesses
- The company has delivered a poor sales growth of 11.3% over past five years.
- Company has high debtors of 159 days.
Peers in Healthcare
| Company | Price | Market cap | P/E | ROE | 1 year |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | ₹1,867.50 | ₹4,48,076 Cr | 40.9 | 14.7% | +8.8% |
| Divi's Laboratories Ltd. | ₹11,080.00 | ₹2,94,139 Cr | 87.5 | 16.2% | +69.4% |
| Torrent Pharmaceuticals Ltd. | ₹4,691.20 | ₹1,78,438 Cr | 84.0 | 27.1% | +22.6% |
| Apollo Hospitals Enterprise Lt | ₹8,771.00 | ₹1,26,114 Cr | 56.2 | 21.9% | +16.9% |
| Laurus Labs Ltd. | ₹2,220.00 | ₹1,19,949 Cr | 89.5 | 18.2% | +125.2% |
| Zydus Lifesciences Ltd. | ₹1,192.00 | ₹1,18,902 Cr | 28.4 | 19.7% | +27.0% |
| Dr. Reddy's Laboratories Ltd. | ₹1,377.90 | ₹1,14,778 Cr | 41.0 | 12.1% | +13.7% |
| Cipla Ltd. | ₹1,394.50 | ₹1,12,658 Cr | 38.9 | 11.8% | -8.0% |
Frequently asked questions
What is the share price of Concord Biotech Ltd.?
Concord Biotech Ltd. (CONCORDBIO) last closed at ₹581.00 (-2.19% on the day).
What is the market cap of Concord Biotech Ltd.?
About ₹6,078 Cr.
What is the P/E ratio of Concord Biotech Ltd.?
The price-to-earnings ratio is 21.6, and return on equity is 13.6%.
Figures are calculated from company results and exchange prices and are for information only.